Mesna does not reduce cisplatin induced nephrotoxicity in the rat

Area of Science:

• Pharmacology
• Toxicology
• Cell Biology

Background:

• Cisplatin is a widely used chemotherapy agent with significant nephrotoxic side effects.
• Mesna is a uroprotective agent often used to mitigate chemotherapy-induced bladder toxicity.

Purpose of the Study:

• To investigate the in vitro and in vivo efficacy of mesna in protecting against cisplatin-induced cytotoxicity and nephrotoxicity.
• To determine the potential therapeutic benefit of combining mesna with cisplatin.

Main Methods:

• In vitro cytotoxicity assays using Chinese hamster cells (V-79-753B) exposed to cisplatin and mesna.
• In vivo studies in rats to evaluate the protective effects of mesna against cisplatin-induced nephrotoxicity.

Main Results:

• Mesna demonstrated significant protection against cisplatin-induced cytotoxicity in vitro.
• No protective effect of mesna against cisplatin-induced nephrotoxicity was observed in vivo in rats.
• The ineffectiveness of mesna in vivo may be due to its stable disulfide form within kidney cells, hindering its reactive thiol group.

Conclusions:

• Mesna's protective mechanism against cisplatin may be cell-specific and not translatable to kidney protection in vivo.
• The combination of mesna and cisplatin is unlikely to offer therapeutic advantages in preventing cisplatin nephrotoxicity in humans.